CAR-T therapy and historical trends in effectiveness and cost–effectiveness of oncology treatments
| Autor: | Darius N. Lakdawalla, Michelle Brauer, Jie Zhang, Zhimei Liu, Yanni Hao, James Baumgardner |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cost–utility analysis
medicine.medical_specialty Receptors Chimeric Antigen Cost effectiveness business.industry Cost-Benefit Analysis Therapies Investigational Health Policy Psychological intervention Antineoplastic Agents Cost-effectiveness analysis History 20th Century History 21st Century Immunotherapy Adoptive Treatment Outcome Neoplasms Emergency medicine medicine Humans Quality-Adjusted Life Years Car t cells business Quality of Health Care |
| Zdroj: | Journal of Comparative Effectiveness Research. 9:327-340 |
| ISSN: | 2042-6313 2042-6305 |
| Popis: | Aim: This study examines how chimeric antigen receptor T-cell (CAR-T) therapy’s incremental effectiveness and cost–effectiveness profile fits into the recent history of anticancer treatments. Materials & methods: We conducted graphical and multivariable analyses using data from the Cost–Effectiveness Analysis Registry of the Tufts Medical Center and the Institute for Clinical and Economic Review’s analysis of CAR-T therapies. We collected additional information including the US FDA approval years for pharmacologic innovations. Results: CAR-T provided 5.03 (95% CI: 3.88–6.18) more incremental quality-adjusted life-years than the average pharmaceutical intervention and 4.61 (95% CI: 1.67–7.56) more than the average nonpharmaceutical intervention, while retaining similar cost–effectiveness. There was evidence of worsening cost–effectiveness by approval year for pharmaceutical interventions. Limitations: Analysis is limited to anticancer treatments studied in cost–utility analyses, estimated to cover approximately 60% of FDA-approved antineoplastic agents. Conclusion: CAR-T therapy breaks a pattern of stagnant efficacy growth in pharmaceutical innovation and demonstrates significantly greater incremental effectiveness and similar cost–effectiveness to prior innovations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|